BioArctic

About Us

BioArctic AB is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. BioArctic focuses on innovative treatments in areas with high unmet medical needs. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Interim Report for the period January – March 2024

Fri, May 17, 2024 08:00 CET

First BrainTransporter technology agreement signed Events during the first quarter 2024 · Leqembi® was approved for the treatment of Alzheimer's disease in China – launch planned for July 2024 · The European Medicines Agency (EMA) announced that its deliberations on lecanemab regarding the Marketing Authorisation Application has been rescheduled due to procedural reasons Events after the end of the period · BioArctic’s partner Eisai submitted a supplemental Biologics License Application (sBLA) for less frequent intravenous (IV) maintenance dosing with lecanemab to the

There are no items matching the current filter

There are no more items matching the current filter

About Us

Interim Report for the period January – March 2024

Subscribe

Media

Share

About Us

Interim Report for the period January – March 2024

Subscribe

Media